Current Report Filing (8-k)
30 5월 2015 - 5:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 29,
2015
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36570 |
|
45-4488360 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
34790 Ardentech Court
Fremont, CA 94555
(Address of principal executive offices) (Zip Code)
(510) 745-1200
Registrants telephone number, including area code
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 29, 2015, we entered into an amendment to our employment agreement with Peter Daddona, Ph.D., our Chief Scientific Officer. Under
the terms of the amendment to the employment agreement, commencing on June 1, 2015, Dr. Daddona will work a part-time schedule as our Chief Scientific Officer and Executive Vice President, Research & Development equivalent to
approximately three (3) full days per week, and his annual base salary and paid vacation will be reduced to $206,875 and 12 days per year, respectively.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION |
|
|
|
|
Dated: May 29, 2015 |
|
|
|
By: |
|
/s/ Vikram Lamba |
|
|
|
|
|
|
Name: |
|
Vikram Lamba |
|
|
|
|
|
|
Title: |
|
President and Chief Executive Officer |
3
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Zosano Pharma Corporation (나스닥)의 실시간 뉴스: 최근 기사 0
More Zosano Pharma Corp News Articles